全文获取类型
收费全文 | 18061篇 |
免费 | 1341篇 |
国内免费 | 435篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 399篇 |
妇产科学 | 59篇 |
基础医学 | 869篇 |
口腔科学 | 16篇 |
临床医学 | 2034篇 |
内科学 | 5813篇 |
皮肤病学 | 12篇 |
神经病学 | 1702篇 |
特种医学 | 1452篇 |
外科学 | 4421篇 |
综合类 | 1933篇 |
现状与发展 | 1篇 |
预防医学 | 213篇 |
眼科学 | 62篇 |
药学 | 584篇 |
4篇 | |
中国医学 | 140篇 |
肿瘤学 | 106篇 |
出版年
2024年 | 10篇 |
2023年 | 410篇 |
2022年 | 501篇 |
2021年 | 1051篇 |
2020年 | 1042篇 |
2019年 | 1011篇 |
2018年 | 863篇 |
2017年 | 639篇 |
2016年 | 546篇 |
2015年 | 740篇 |
2014年 | 1164篇 |
2013年 | 1236篇 |
2012年 | 800篇 |
2011年 | 964篇 |
2010年 | 760篇 |
2009年 | 779篇 |
2008年 | 813篇 |
2007年 | 722篇 |
2006年 | 697篇 |
2005年 | 619篇 |
2004年 | 525篇 |
2003年 | 451篇 |
2002年 | 416篇 |
2001年 | 344篇 |
2000年 | 240篇 |
1999年 | 211篇 |
1998年 | 210篇 |
1997年 | 185篇 |
1996年 | 189篇 |
1995年 | 160篇 |
1994年 | 157篇 |
1993年 | 163篇 |
1992年 | 140篇 |
1991年 | 132篇 |
1990年 | 115篇 |
1989年 | 93篇 |
1988年 | 75篇 |
1987年 | 84篇 |
1986年 | 76篇 |
1985年 | 80篇 |
1984年 | 90篇 |
1983年 | 54篇 |
1982年 | 66篇 |
1981年 | 60篇 |
1980年 | 35篇 |
1979年 | 34篇 |
1978年 | 24篇 |
1977年 | 15篇 |
1976年 | 17篇 |
1973年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
〔摘 要〕 目的:探讨急性 A 型主动脉夹层(ATAAD)患者的计算机断层血管成像检查(CTA)表现并分析患者突发死
亡的危险因素。方法:回顾性分析 2018 年 1 月至 2020 年 12 月在福建省立医院因急性胸痛入院并确诊 ATAAD 的患者 96 例,
根据患者发病 48 h 内是否突发死亡,分为死亡的观察组 13 例,未死亡的对照组 83 例。比较两组患者的 CTA 表现,采用
logistic 回归分析 ATAAD 患者发生死亡的危险因素。结果:多因素 logistic 回归分析提示:CTA 表现中真腔严重闭塞、冠状
动脉受累及、撕裂至髂分叉以远是患者发生死亡的危险因素。结论:ATAAD 患者的 CTA 提示有真腔严重闭塞、冠状动脉
受累及、撕裂至髂分叉以远时,患者的猝死率风险较高,需要紧急干预处置并尽早手术治疗。 相似文献
102.
目的调查分析Stanford A型主动脉夹层术后肾脏功能损伤(AKI)的危险因素,为临床降低肾脏功能损伤并发率对策提供支持。方法收集2017年1月—2019年12月医院心血管外科确诊且顺利行A型主动脉夹层手术的179例患者为研究对象,均由同组外科医师和麻醉医师实施手术,术后进入ICU监测治疗。根据术后早期是否存在AKI,将发生AKI 60例设为病例组,未发生AKI 119例设为对照组。分析发生AKI高危因素。结果经过多因素Logistics回归分析显示,年龄(OR=2.396)、双侧肾脏灌注欠佳(OR=8.725)、BMI值(OR=3.454)、监测膀胱温度(OR=4.180)、CPB时长(OR=2.165)、术中红细胞输注(OR=2.291)均为此类手术患者发生AKI独立危险因素(P<0.05)。结论年龄、BMI值、双侧肾脏灌注欠佳、CPB、监测膀胱温度、术中红细胞输注均为影响A型主动脉夹层术后AKI的独立相关因素,临床护士应针对上述分析制定个体化针对方案以降低术后AKI发生风险。 相似文献
103.
Kevin L. Greason Juan A. Crestanello Katherine S. King Gabor Bagameri Sertac M. Cicek John M. Stulak Richard C. Daly Joseph A. Dearani Hartzell V. Schaff 《The Journal of thoracic and cardiovascular surgery》2021,161(1):12-20.e2
BackgroundThere is controversy regarding the extent of aortic resection necessary in patients with aortopathy related to bicuspid aortic valve disease. To address this issue, we reviewed our experience in patients undergoing ascending aorta replacement during bicuspid aortic valve replacement.MethodsWe reviewed 702 patients who underwent ascending aorta replacement at the time of initial nonemergent native bicuspid aortic valve replacement at our institution between January 2000 and June 2017. Treatment cohorts included an open hemiarch replacement group (n = 225; 32%) and a clamped ascending aorta replacement group (n = 477; 68%).ResultsMedian patient age was 60 years (interquartile range [IQR], 51-67 years), female sex was present in 113 patients (16%), ejection fraction was 62% (IQR, 56%-66%), and aortic arch diameter was 33 mm (IQR, 29-36 mm). Cardiopulmonary bypass time was longer in the hemiarch replacement group (188 minutes vs 97 minutes; P < .001). Procedure-related complications (36%) and mortality (<1%) were similar in the 2 groups; however, the hemiarch group had an increased odds of blood transfusion (odds ratio, 1.62; 95% confidence interval [CI], 1.15-2.28; P = .006). The median duration of follow-up was 6.0 years (95% CI, 5.3-6.8 years). Overall survival was 94 ± 1% at 5 years and 80 ± 2% at 10 years. Multivariable analysis demonstrated similar survival in the 2 groups (hazard ratio, 0.83; 95% CI, 0.51-1.33; P = .439). No repeat aortic arch operations were done for aortopathy over the duration of clinical follow-up.ConclusionsCompared with patients in the clamped ascending aorta replacement group, patients in the hemi-arch replacement group had longer cardiopulmonary bypass and aortic cross-clamp times, along with an increased risk of blood transfusion, but similar freedom from repeat aortic arch operation and survival. We identified no advantage of performing hemiarch replacement in the absence of aortic arch dilation. 相似文献
104.
《Clinical microbiology and infection》2020,26(8):999-1007
BackgroundTranscatheter aortic valve implantation (TAVI) has been approved for the treatment of severe aortic stenosis since 2008 and recent trials have shown that TAVI is at least non-inferior to surgical aortic valve replacement (SAVR) with regards to short-term efficacy and safety in patients across all surgical risk profiles. Prosthetic valve endocarditis of the transcatheter heart valve is a feared complication; data on the risk of infective endocarditis (IE) subsequent to TAVI are now gradually emerging.ObjectivesWe set forth to conduct a review of the incidence, diagnosis, microbial aetiologies, prevention, outcome and management of TAVI-IE.SourcesFrom the MEDLINE database we included a total of 12 observational studies and five studies of long-term results from randomized controlled trials.ContentThe incidence of TAVI-IE was reported to be between 0.7% and 3.0% per person-year. The most common microbes were reported to be enterococci, Staphylococcus aureus, streptococci and coagulase-negative staphylococci. International guidelines on prevention strategies of IE recommend good sanitary conditions including cutaneous care, good oral hygiene and good care of dialysis catheters. Antibiotic prophylaxis is recommended by guidelines prior to dental procedures in patients with TAVI; however, evidence is sparse. The majority of the patients included in this review with TAVI-IE had an indication for surgical intervention due to IE (50.0% or more); however, only a small subset of the patients underwent surgery (16.4% or less). The in-hospital mortality was around 25%, i.e. of the same order of magnitude as in prosthetic valve IE in general, but varied substantially between studies (from 11% to 64%).ImplicationsThe US Food and Drug Administration's approval of TAVI in patients at low surgical risk may change the characteristics of patients with TAVI, which may influence the incidence, management, and outcome of patients with TAVI-IE. 相似文献
105.
Claudia R. L. Cardoso Christian N. Roderjan Aline H. Cavalcanti Arthur F. Cortez Elizabeth S. Muxfeldt Gil F. Salles 《Journal of sleep research》2020,29(4)
Resistant hypertension (RHT) is associated with obstructive sleep apnea (OSA) and increased aortic stiffness, measured by carotid‐femoral pulse wave velocity (cf‐PWV). We aimed to evaluate in a randomized controlled trial, the effect of Continuous positive airway pressure (CPAP) treatment on cf‐PWV in comparison with a control group in patients with RHT and moderate‐severe OSA. One‐hundred and sixteen patients were randomized to 6‐month CPAP treatment (56 patients) or no therapy (60 patients), while keeping their antihypertensive treatment unchanged. Carotid‐femoral pulse wave velocity was performed at the beginning and end of the 6‐month period. Intention‐to‐treat intergroup differences in cf‐PWV changes were assessed by a generalized mixed‐effects model with the allocation group as a fixed factor and adjusted for age, sex, changes in mean arterial pressure and the baseline cf‐PWV values. Subgroup sensitivity analyses were performed, excluding patients with low CPAP adherence and low cf‐PWV at baseline. CPAP and control groups had similar clinic‐laboratorial characteristics. Patients had a mean cf‐PWV of 9.4 ± 1.6 m/s and 33% presented cf‐PWV > 10 m/s. During treatment, the control group had a mean increase in cf‐PWV of +0.43 m/s (95% confidence interval [CI], +0.14 to +0.73 m/s; p = .005), whereas the CPAP group had a mean increase of +0.03 m/s (95% CI, ?0.33 to +0.39 m/s; p = .87), resulting in a mean difference in changes between CPAP and control of ?0.40 m/s (95% CI, ?0.82 to +0.02 m/s; p = .059). Subgroup analyses did not change the results. In conclusion, a 6‐month CPAP treatment did not reduce aortic stiffness, measured by cf‐PWV, in patients with RHT and moderate/severe OSA, but treatment may prevent its progression, in contrast to no‐CPAP therapy. 相似文献
106.
《Archives of Cardiovascular Diseases》2020,113(4):263-275
The difficult balance between thrombosis and bleeding after transcatheter aortic valve replacement. TAVR: transcatheter aortic valve replacement. 相似文献
107.
108.
109.
110.